Skip to main content
. Author manuscript; available in PMC: 2011 Sep 19.
Published in final edited form as: Breast Dis. 2008;29:91–103. doi: 10.3233/bd-2008-29110

Fig. 5.

Fig. 5

Potential for Cripto-1 as a Biomarker for Cancer and Therapeutic Target. A) Cripto-1 is expressed in breast cancer tissue and in plasma samples from breast cancer patients. B) Effect of anti-Cripto-1 monoclonal blocking antibody on growth of NCCIT human teratocarcinoma cells in vivo. Anti-Cripto-1 blocking antibody negatively affects growth of NCCIT in a xenograft model.